Ventyx Biosciences (VTYX) Stock Price, News & Analysis

Company Overview

Ventyx Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in Cambridge, Massachusetts, the company employs a proprietary modular platform to engineer antibody-based fusion proteins designed to deliver potent cytokines selectively to tumor cells and the tumor microenvironment. Since its founding, Ventyx has positioned itself at the forefront of next-generation immuno-oncology by combining established biologic modalities with precision delivery.

The company’s lead asset, modakafusp alfa, is an engineered antibody-IFNα fusion designed to target CD38-expressing cells in hematological malignancies, including multiple myeloma. In addition to hematologic indications, Ventyx is advancing multiple preclinical and early clinical programs aimed at solid tumors, leveraging its platform to explore diverse cytokine payloads. Ventyx’s pipeline reflects a strategic balance of internal discovery and external collaborations, with research partnerships to expand the reach of its technology into new therapeutic areas.

Ventyx operates across North America and Europe, conducting clinical trials in major oncology centers to ensure broad patient access and efficient data collection. The company collaborates with contract research organizations, academic institutions and pharmaceutical partners to accelerate development timelines and optimize regulatory strategies. Its integrated development model supports seamless transitions from preclinical to clinical stages, reinforcing Ventyx’s commitment to rigorous scientific validation.

Under the leadership of CEO Petros Efthymiou, Ventyx Biosciences is guided by a management team with deep experience in biologics R&D, regulatory affairs and commercial strategy. The board of directors comprises seasoned industry executives and investors who have successfully advanced therapeutic candidates through registration and market launch. With a clear focus on innovation and targeted delivery, Ventyx aims to address unmet needs in oncology and deliver meaningful improvements in patient outcomes.

Key Stats

• Today's Range: $2.72 to $2.84
• 50-Day Range: $1.17 to $2.84
• 52-Week Range: $0.78 to $3.39
• Volume: 986,672 shs
• Average Volume: 1.43 million shs
• Market Capitalization: $194.98 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $10.00
• Consensus Rating: Moderate Buy

Ventyx Biosciences Stock Analysis - MarketRank™

Ventyx Biosciences scored higher than 70% of companies evaluated by MarketBeat, and ranked 302nd out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Ventyx Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Ventyx Biosciences has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Ventyx Biosciences are expected to decrease in the coming year, from ($2.09) to ($2.11) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Ventyx Biosciences is -1.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Ventyx Biosciences is -1.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Ventyx Biosciences has a P/B Ratio of 0.76. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.01% of the float of Ventyx Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Ventyx Biosciences has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Ventyx Biosciences has recently decreased by 99.89%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Ventyx Biosciences does not currently pay a dividend.

Dividend Growth

Ventyx Biosciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.01% of the float of Ventyx Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Ventyx Biosciences has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Ventyx Biosciences has recently decreased by 99.89%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 1.30

News Sentiment

Ventyx Biosciences has a news sentiment score of 1.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.99 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Ventyx Biosciences this week, compared to 2 articles on an average week.

Search Interest

6 people have searched for VTYX on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Ventyx Biosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

14.49% of the stock of Ventyx Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

97.88% of the stock of Ventyx Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

VTYX Stock Analysis - Frequently Asked Questions

How have VTYX shares performed this year?

Ventyx Biosciences' stock was trading at $2.19 at the beginning of the year. Since then, VTYX stock has increased by 25.1% and is now trading at $2.74.

How were Ventyx Biosciences' earnings last quarter?

Ventyx Biosciences, Inc. (NASDAQ:VTYX) announced its quarterly earnings results on Thursday, May, 8th. The company reported ($0.39) EPS for the quarter, beating the consensus estimate of ($0.48) by $0.09.

When did Ventyx Biosciences IPO?

Ventyx Biosciences (VTYX) raised $152 million in an IPO on Thursday, October 21st 2021. The company issued 9,472,656 shares at a price of $15.00-$17.00 per share.

Who are Ventyx Biosciences' major shareholders?

Top institutional shareholders of Ventyx Biosciences include Wealth Enhancement Advisory Services LLC (0.04%) and Pallas Capital Advisors LLC (0.03%). Insiders that own company stock include Somu Subramaniam, Nsv Partners Iii Lp, Raju Mohan, John Nuss, Christopher W Krueger, Sheila Gujrathi, William J Sandborn and Martin Auster.
View institutional ownership trends.

How do I buy shares of Ventyx Biosciences?

Shares of VTYX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Ventyx Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Ventyx Biosciences investors own include Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), SPDR S&P 500 ETF Trust (SPY), JPMorgan Chase & Co. (JPM) and Netflix (NFLX).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 7/13/2025
• Next Earnings (Estimated): 8/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:VTYX
• CIK: 1851194
• Web: www.ventyxbio.com
• Phone: 760-593-4832
• Fax: N/A
• Employees: 30
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Ventyx Biosciences: $10.00
• High Price Target: $14.00
• Low Price Target: $6.00
• Potential Upside/Downside: +265.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.75)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$135.12 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -47.45%
• Return on Assets: -43.49%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 19.57
• Quick Ratio: 19.57

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.59 per share
• Price / Book: 0.76

Miscellaneous

• Outstanding Shares: 71,160,000
• Free Float: 60,850,000
• Market Cap: $194.98 million
• Optionable: Optionable
• Beta: 0.93